DMAC — DiaMedica Therapeutics Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1401040 ·
Last close
$8.38
Market Cap
$452.16M
52W High
$11.00
52W Low
$5.24
ADV30
221,332
Next earnings
2026-11-12
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -11,621,000 -11,310,000 36,153,000 6,800,000 7,494,000
Jun 2026 0 — -10,498,000 -10,139,000 45,001,000 5,129,000 6,663,000
Mar 2026 0 — -10,482,000 -10,042,000 53,080,000 4,868,000 5,845,000
Dec 2025 0 — -9,213,000 -8,740,000 61,371,000 15,647,000 5,260,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-31,511,000
Investing CF
$-11,642,000
Financing CF
$44,173,000
CapEx
$-33,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.73
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-192,949,000
Inventory
—
Receivables
$244,000
ST Investments
$38,375,000
EBIT TTM
$-39,226,000
Pretax Income TTM
$-37,511,000
Interest Exp TTM
—
Analysts
4

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -34,397,000 -32,766,000 61,371,000 5,260,000 56,111,000 -29,062,000
Dec 2024 0 -26,681,000 -24,444,000 46,345,000 5,627,000 40,718,000 -22,076,000
Dec 2023 0 -21,267,000 -19,381,000 54,160,000 3,103,000 51,057,000 -18,728,000
Dec 2022 0 -14,001,000 -13,676,000 34,395,000 2,568,000 31,827,000 -11,511,000

TTM Snapshot

Revenues TTM
$-45,000
NetIncome TTM
$-37,541,000
OpCashFlow TTM
—
Assets (Latest)
$45,001,000
Forward EPS
$-0.75

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $5.00 · spot: $8.59 · call volume: 112 · put volume: 55
Expected Move to 2027-01-15: ±$3.63 (42.32%) — implied range $4.96 – $12.23 · ATM straddle on $7.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
PHAT Phathom Pharmaceuticals, Inc. $447.10M $5.50 —
ARVN ARVINAS, INC. $446.61M $6.82 —
ASMB ASSEMBLY BIOSCIENCES, INC. $460.74M $22.50 —
EOLS Evolus, Inc. $442.80M $6.69 —
INDP Indaptus Therapeutics, Inc. $442.36M $3.32 —

News headlines (Yahoo Finance, 1h cache)

DiaMedica (DMAC) Q3 2026 Earnings Call Transcript
2026-11-13 20:45 · Yahoo
DiaMedica Therapeutics Q3 Earnings Call Highlights
2026-11-13 15:14 · Yahoo
DiaMedica Therapeutics Inc. Q3 2026 Earnings Call Summary
2026-11-13 13:30 · Yahoo
DiaMedica Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
2026-11-12 21:30 · Yahoo
DiaMedica Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Business Update November 13, 2026
2026-11-05 13:45 · Yahoo
DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
2026-10-22 12:00 · Yahoo
DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar
2026-10-19 12:00 · Yahoo
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results
2026-09-30 12:30 · Yahoo
DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
2026-09-02 12:30 · Yahoo
Wall Street Analysts Think DiaMedica Therapeutics (DMAC) Could Surge 129.97%: Read This Before Placing a Bet
2026-08-26 13:55 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.